DS Biopharma appoints Jane Hollingsworth as Non-Executive Director

Dublin, Ireland, February 7, 2017 – DS Biopharma (DS), a clinical stage biopharmaceutical company, today announced the appointment of Jane Hollingsworth as a non-executive director to the company’s Board.

Jane is co-founder and former CEO of NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on diseases of the central nervous system which was sold to Teva in 2014. She also co-founded and served as Executive Vice President of Auxilium Pharmaceuticals (NASDAQ: AUXL), a biopharmaceutical company focused on urology which was sold to Endo Pharmaceuticals in 2015. Prior to launching and leading these two successful biopharmaceutical companies, Jane was VP, Secretary & General Counsel of IBAH, Inc. (NASDAQ: IBAH), a multinational clinical research organization. Before joining IBAH, she practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.

Jane is currently Executive Chair of Talee Bio, a gene therapy company focused on cystic fibrosis as well as diseases of the lung and Managing Partner of Militia Hill Ventures. She is a leader in the entrepreneurial and life sciences communities and serves on various industry and community boards, including Talee Bio, S1 Biopharma, the University City Science Center, the Kimmel Center for the Performing Arts, Breastcancer.Org and the Wilma Theater.

“I am delighted to welcome Jane to the DS Board of Directors,” commented Dr. John Climax, Executive Chairman of DS. “She has an exemplary track record in building pharma companies and will be a great addition to the DS Board of Directors”.

About DS Biopharma

DS Biopharma, headquartered in Dublin, Ireland, is a privately held, clinical stage, pharmaceutical drug discovery and development company, which develops new medicines for unmet needs in dermatological diseases. The compounds under development are based on a novel bioactive lipid platform. These lipid molecules have been shown to be crucial to the pathways of several conditions including skin disorders such as atopic dermatitis (AD), acne and psoriasis.



DS Biopharma: investorrelations@dsbiopharma.com, +35312933590